Changes in Cardiovascular Biomarkers Associated With the Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes
Patrick R. Lawler(McGill University Health Centre), David Z.I. Cherney(University Health Network), Leif E. Lovblom(University of Toronto), Hongyan Liu(University of Toronto), Davor Brinc(University Health Network), Yuliya Lytvyn(University Health Network), Kevin D. Burns(University of Ottawa), Claudia Frankfurter(University of Toronto), Dylan Burger(University of Ottawa)
Cited by 37
Related Papers
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines
|Journal of Extracellular Vesicles|2018|11.4k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
|JAMA|2020|884
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
|Bristol Research (University of Bristol)|2021|589
Molecular Basis for the Regulation of Angiogenesis by Thrombospondin-1 and -2
|Cold Spring Harbor Perspectives in Medicine|2012|546